Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Stock Transferred to Nasdaq Capital Market

NEW YORK (GenomeWeb News) – Compugen today said that its application to transfer its common stock from the Nasdaq Global Market to the Nasdaq Capital Market has been approved by the exchange.

The transfer was effective as of the opening of the stock market this morning. Compugen's shares continue to trade under the symbol "CGEN."

The transfer of Compugen's shares was not unexpected. Earlier this month, the firm said that it had received a letter from Nasdaq stating that the firm is currently not in compliance with listing regulations. Specifically, the exchange said that Compugen is not in compliance with regulations that state that it must have at least $10 million in stockholders' equity.

At the time, the firm said that it believes it is in compliance with the listing requirements for the Nasdaq Capital Market.

In early Wednesday trade, shares of Compugen were up 4 percent at $1.25.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.